Working... Menu
Trial record 69 of 157 for:    eribulin

Study of E7389 for Advanced or Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00965523
Recruitment Status : Completed
First Posted : August 25, 2009
Results First Posted : August 15, 2013
Last Update Posted : August 15, 2013
Information provided by (Responsible Party):
Eisai Inc. ( Eisai Co., Ltd. )

Brief Summary:
The purpose of this study (E7389-J081-224; hereafter referred to as Study 224) is to evaluate the safety of patients who continue to receive E7389 after completing the Phase II clinical study (E7389-J081-221; hereafter referred to as Study 221) of E7389 for advanced or relapsed breast cancer by intravenously administering E7389.

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: Eribulin Mesylate Phase 2

Detailed Description:
Study 224 (Extension Period) was designed to evaluate the safety and efficacy of E7389 by collecting data from subjects who continued receiving E7389 after being transferred from Study 221 (Core Period). Thus, efficacy analyses performed in Study 221 were updated and reported with the additional data collected in Study 224. Objective response rate (ORR) and the number of subjects with adverse events are reported as outcome measures because these were the outcome measures of Study 221 which is a main study in the combined data. Also, safety analyses performed in Study 221 were updated and reported with the additional data collected in Study 224.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 81 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Extension Study of E7389 for Locally Advanced or Metastatic Breast Cancer
Study Start Date : January 2008
Actual Primary Completion Date : December 2010
Actual Study Completion Date : January 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Eribulin Mesylate Drug: Eribulin Mesylate
Eribulin mesylate 1.4 mg/m^2 intravenous infusion (IV) given over 2 to 5 minutes on Day 1 and 8 every 21 days.

Primary Outcome Measures :
  1. Number of Subjects With Adverse Events. [ Time Frame: Every week during treatment and up to 30 days after last dose of study treatment ]

Secondary Outcome Measures :
  1. Objective Response Rate (ORR) as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) [ Time Frame: Every 6 weeks ]
    Objective response measured by Response Evaluation Criteria In Solid Tumors (RECIST) criteria and is Complete Response (disappearance of all target lesions) plus Partial Response (at least 30% decrease in sum of longest diameter [LD] of target lesions compared baseline sum of LD). Tumor assessments every 6 weeks.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 74 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion criteria:

  1. Female patients with histologically or cytologically confirmed breast cancer.
  2. Patients who have received prior chemotherapy including anthracycline and taxane.
  3. Patients aged 20 - 74 years when giving informed consent and who have given written voluntary consent for participating in this study before the completion of Study 221.
  4. Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2.
  5. Patients with a measurable lesion.
  6. Patients with an expected survival of ≥ 3 months from the start of study drug therapy.
  7. Female patients in whom continued administration of E7389 following Study 221 will be useful.
  8. Patients who have met the criteria for starting the next cycle in Study 221.

Namely, patients who meet all of the following criteria:

  1. Neutrophil count >= 1,500 /µL
  2. Platelet count >= 100,000 /µL
  3. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <= 2.5 times the upper limit of normal (ULN) in the facility or <= 5 times ULN in patients with hepatic metastasis)
  4. Total bilirubin <= 1.5 times ULN
  5. Serum creatinine <= 1.5 times ULN
  6. Non-hematological toxicity <= Grade 2 (excluding disease-associated events and laboratory abnormalities without clinical symptoms)

Exclusion criteria:

  1. Patients with systemic infection with a fever (≥38.0°C).
  2. Patients with pleural effusion, ascites or pericardial fluid requiring drainage.
  3. Patients with brain metastasis presenting clinical symptoms.
  4. Pregnant women, nursing mothers, or premenopausal women of childbearing potential. Premenopausal women of childbearing potential are defined as women who are <12 months after the latest menstruation and are positive in pregnancy test performed for enrollment or who have not taken the test and do not consent to take an appropriate contraceptive measure. Post-menopausal women must be amenorrheic for at least 12 months to make sure that they have no potential for becoming pregnant.
  5. Patients with serious complications:

    1. Patients with uncontrollable cardiac disease such as ischemic heart disease and arrhythmia at a level of severity that needs to be treated (excluding left ventricular hypertrophy, mild left ventricular volume overload and mild right leg block that accompany hypertension)
    2. Patients with myocardial infarction within 6 months prior to study entry
    3. Patients with a complication of hepatic cirrhosis
    4. Patients with interstitial pneumonia and pulmonary fibrosis
    5. Patients with a bleeding tendency
  6. Patients with an active double cancer.
  7. Pregnant women or nursing mothers.
  8. Patients who have received extensive radiotherapy (≥30% of bone marrow).
  9. Patients who refuse to receive the supportive therapy of blood transfusion for myelosuppression.
  10. Patients who are participating in other clinical studies.
  11. Patients who are judged by the principal investigator or the other investigators to be inappropriate as patients in this clinical study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00965523

Layout table for location information
Nagoya, Aichi, Japan
Kure, Hiroshima, Japan
Chuo, Tokyo, Japan
Fukuoka, Japan
Kagoshima, Japan
Sponsors and Collaborators
Eisai Co., Ltd.
Layout table for investigator information
Study Director: Tatsuo Watanabe Oncology Clinical Development Section. JAC PCU., Eisai, Co., Ltd

Layout table for additonal information
Responsible Party: Eisai Co., Ltd. Identifier: NCT00965523     History of Changes
Obsolete Identifiers: NCT00633100
Other Study ID Numbers: E7389-J081-224
First Posted: August 25, 2009    Key Record Dates
Results First Posted: August 15, 2013
Last Update Posted: August 15, 2013
Last Verified: July 2013

Keywords provided by Eisai Inc. ( Eisai Co., Ltd. ):
breast cancer

Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases